comparemela.com

Latest Breaking News On - Jan mikkelsen - Page 3 : comparemela.com

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

United statesJessica fyeJoseph schwartzTim leeDavid lebowitzAscendis pharmaLi watsekStina singelJan mikkelsenJoe kellyScott smithTazeen ahmadTimothy leeHead of clinical developmentEuropean commissionCall transcript february

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal App.

United statesAscendis pharmaMelinda bakerTim leeJan mikkelsenEyconis incPatti bankExchange commissionChief executiveEurope directInternational marketsEndocrinology rare diseaseBiologics license applicationPrescription drug user fee actNew drug applicationInvestigational new drug

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism -January 31, 2024 at 04:02 pm EST

COPENHAGEN, Denmark, Jan. 31, 2024 Ascendis Pharma A/S today announced that YORVIPATH® , a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic.

United kingdomUnited statesAscendis pharma transconTim leeMelinda bakerJan mikkelsenAscendis pharmaUs food drug administrationEndocrine society guidelinesPatti bankExchange commissionEuropean commissionInternational consensus statementGlobenewswire incTeijin ltdEuropean society of endocrinology consensus statement

Ascendis Pharma (ASND) Launches YORVIPATH

Ascendis Pharma (ASND) Launches YORVIPATH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ascendis pharma transconJan mikkelsenAscendis pharmaChief executiveEndocrinology rare disease

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created

United statesRedwood cityConrad wangDanna chenEmmett cunninghamDaniel estesAscendis pharmaYvonne yamanakaJan mikkelsenOliver boris stauchFrazier life sciences of eyconis incExchange commissionFrazier life sciencesSenior partnerHealthquest capitalExecutive chairman

vimarsana © 2020. All Rights Reserved.